Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The United Laboratories International Holdings ( (HK:3933) ) just unveiled an update.
The United Laboratories International Holdings has reported successful completion of a Phase II clinical trial in Chinese Type 2 diabetes patients for its Class 1 innovative drug UBT251 Injection, a long-acting triple agonist targeting GLP-1, GIP and glucagon receptors. In a randomized, double-blind study versus placebo and semaglutide, UBT251 achieved greater reductions in HbA1c, body weight and several cardiometabolic markers, while demonstrating a safety and tolerability profile consistent with other triple-G agonists.
The positive Phase II data support advancing UBT251 into Phase III trials in Chinese patients with Type 2 diabetes, underscoring the company’s ambitions in high-growth diabetes, obesity, CKD and MASH treatment areas. Having secured approvals for multiple indications in China and the U.S. and an exclusive licensing agreement with Novo Nordisk for UBT251, the group strengthens its strategic position in next-generation metabolic therapies and enhances the potential value proposition for partners and investors.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
More about The United Laboratories International Holdings
The United Laboratories International Holdings is a pharmaceutical group focused on innovative drug development, particularly in metabolic and chronic disease treatments. Through its wholly owned unit The United Bio-Technology (Hengqing) Co., it is advancing long-acting peptide-based therapies and holds a leading position in China’s triple-agonist diabetes and obesity drug pipeline.
Average Trading Volume: 11,348,779
Technical Sentiment Signal: Hold
Current Market Cap: HK$19.93B
For an in-depth examination of 3933 stock, go to TipRanks’ Overview page.